Bio­gen CEO Vounatsos laments 'con­fu­sion' and 'mis­in­for­ma­tion' lead­ing to chal­lenges with Aduhelm up­take

Bio­gen CEO Michel Vounatsos on Thurs­day ad­mit­ted the com­pa­ny is ex­pe­ri­enc­ing some “near term chal­lenges” in launch­ing its con­tro­ver­sial new Alzheimer’s drug, a lit­tle more than two months since win­ning an ac­cel­er­at­ed ap­proval.

“There is clear­ly too much con­fu­sion, mis­in­for­ma­tion and con­tro­ver­sy sur­round­ing our da­ta and the ap­proval process,” Vounatsos said at a JP Mor­gan health care con­fer­ence. In­deed, the HHS In­spec­tor Gen­er­al has opened an in­ves­ti­ga­tion in­to the ap­proval, in ad­di­tion to an in­ter­nal FDA in­ves­ti­ga­tion, which was re­vealed by a Con­gres­sion­al in­ves­ti­ga­tion in­to the ap­proval and the close ties be­tween FDA and Bio­gen.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER